Test Fact Sheet

◥ Clinical Significance (Use)

CertuitAD is an *in vitro* immunoassay that measures plasma tau protein fragments phosphorylated at threonine 217 (P-tau217), using the Quanterix SP-X Imaging and Analysis System™. CertuitAD is intended to be used in patients aged 60 years and older who present with cognitive impairment and who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline.

The CertuitAD test should be used as part of a comprehensive diagnostic work-up. It is reported as a qualitative result (*positive, negative,* or *indeterminate*). Assay results correlate highly with the presence or absence of amyloid deposition as measured by amyloid PET scan. In a clinical validation set, a positive result had a sensitivity of 91%, a negative result had a specificity of 90%, and 18% of results were indeterminate.[1]

This test by itself cannot establish a diagnosis of AD and is not a substitution for thorough clinical evaluation. As with any diagnostic test, physicians should consider the test result and assay performance characteristics in conjunction with other clinical findings such as individual cognitive assessment, other laboratory/imaging findings, and genetic testing.

This laboratory developed test (LDT) is not intended to be used as a screening or stand-alone diagnostic test and is not intended for therapeutic monitoring.

[1]Reported values for sensitivity (of a positive result) and specificity (of a negative result) were calculated without including indeterminate results. Similarly, an indeterminate result does not have a calculated sensitivity or specificity.

◥ Clinical Background/Disease Overview

Historically, AD has been defined as a clinical syndrome of cognitive impairment with two hallmark neuropathologies in brain tissue: neuritic (amyloid) plaques and neurofibrillary tangles (NFTs) composed of tau protein. These pathologies underlay neuropathological definitive diagnosis for decades and formed the basis for the current National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria for diagnosis (Hyman et al., 2012; Jack et al., 2018). Outside of tissue assessment, in-life diagnosis of Alzheimer's disease has been largely based on symptomatic presentation and elimination of alternate etiologies for cognitive and neurobehavioral changes. However, the recent emergence of PET tracers and CSF assays with high sensitivity and specificity for detection of amyloid and tau pathology has facilitated an evolution towards a biological definition of AD. This biological construct for AD is built on assessment of three principal pathologies: **a**myloid plaques, NFTs composed of **t**au protein, and **n**eurodegeneration, i.e., the "ATN" model initially proposed as a research framework by NIA-AA (Jack et al., 2013, Jack et al., 2016). In 2023, the NIA-AA outlined a revision to the ATN construct which contained more comprehensive use of blood and fluid biomarkers (Jack et al., 2024 in press).

The ATN construct allows for a biomarker-based categorization of a disease spectrum, the Alzheimer's continuum which includes both amyloid-related pathologic changes and AD itself; the former is defined by evidence of amyloid deposition only, while AD is defined by evidence of both amyloid and tau pathologies, with or without neurodegeneration. Within the ATN construct, both radiologic and laboratory biomarkers are used to assess for a patient's ATN profile and thereby determine presence of disease (Jack et al., 2018).

Until recently, laboratory assessment for amyloid and tau pathology has been limited to analysis of CSF for amyloid beta protein or phosphorylated tau (P-tau), and development of blood-based markers has been of high importance (Hansson et al., 2023). Assays measuring P-tau in blood have shown P-tau levels to be associated with the presence of both amyloid plaque and NFT pathologies (Mielke et al., 2018). High diagnostic accuracy of P-tau has been demonstrated in two recent studies that included non-AD subjects (Palmqvist et al., 2020 and Thijssen et al., 2020). In addition, analysis of P-tau along with other AD biomarkers demonstrated that elevation of P-tau occurs during the earliest stages of AD (Palmqvist et al., 2019). Assays measuring P-tau217, in particular, show high diagnostic accuracy for AD compared to other neurodegenerative diseases (Palmqvist et al., 2020).

CertuitAD specifically measures phosphorylated fragments of tau, P-tau217, and has shown a strong correlation with amyloid PET scan in a cohort of 2071 clinical trial participants, using a PET positivity cut-off of 24 Centiloids, i.e., early phase disease. Thus, CertuitAD may aid in the early evaluation of AD in patients experiencing cognitive decline.

◥ Individuals Suitable for Testing
Patients aged 60 years and older who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. This test must be ordered by a health care provider.

◥ Clinical Test Method
Chemiluminescent immunoassay.

◥ Test Limitations
CertuitAD results must be interpreted in the setting of a thorough clinical evaluation. CertuitAD is not intended to be used as a screening or stand-alone diagnostic test and is not intended for therapeutic monitoring. A positive result by itself does not establish a diagnosis of AD. Additional laboratory testing (such as *APOE* genotyping) may be warranted based on the patient's clinical presentation and/or family history.

◥ Clinical Characteristics
Clinical validation of CertuitAD was performed in a large, multicenter trial population of 2071 participants aged 60 and over who presented with cognitive decline and who did not have significant comorbidities, consisting of 54% females and 46% males, with 89% participants self-identifying race as White, 6% as Asian, 4% as Black, and 1% as other racial groups, and with 14% identifying as Hispanic/Latino by ethnicity.

In this trial population, a positive CertuitAD result demonstrated a positive predictive value (PPV[1]) of 95%, as compared to amyloid PET scan result. PPV represents the probability that a patient will have a disease or condition (in this case, amyloid deposition), given a positive test result.

In the same trial population, a negative CertuitAD result demonstrated a negative predictive value (NPV[1]) of 84%, as compared to amyloid PET scan result. NPV represents the probability that a person does not have a disease or condition (in this case, amyloid deposition), given a negative test result. It is worthwhile to note that in trial participants carrying the *APOE ε4* genotype (hetero- or homozygous), the NPV of a negative CertuitAD result decreased to 65%. Therefore, correlation of a negative result with genetic testing may be warranted if there is strong clinical suspicion for Alzheimer's disease, bearing in mind that the clinical risk conferred by *APOE* status varies with race and ethnicity (Belloy et al., 2023).

[1]Indeterminate results were not included in PPV and NPV calculations.

◥ Interpretative Information
A test result reported as **negative** is consistent with absence of amyloid deposition in brain as measured by amyloid PET scan, using a cut-off <24 Centiloids to define a negative scan. A negative CertuitAD result reduces the likelihood that a patient's cognitive impairment is due to AD.

A test result reported as **positive** is consistent with the presence of amyloid deposition in brain as measured by amyloid PET scan, using a cut-off of ≥24 Centiloids to define a positive scan. Note that a positive CertuitAD result by itself does not establish a diagnosis of AD or other cognitive disorder.

A test result reported as **indeterminate** indicates that amyloid plaques may or may not be present. Additional diagnostic testing, such as other laboratory testing or amyloid PET scan, should be considered based on clinical presentation. If symptomatology persists or evolves, repeat testing may be helpful.

CertuitAD results must be interpreted in conjunction with other patient clinical information, which may include other laboratory and radiographic findings, as well as genetic testing. CertuitAD is not intended to be used as a screening or stand-alone diagnostic test and is not intended for therapeutic monitoring.

LDT Statement and Geographic Limitations

This laboratory developed test (LDT) was developed and its performance characteristics determined by Eli Lilly Clinical Diagnostics Laboratory, LLC (ELCDL). The US Food and Drug Administration (FDA) has not approved or cleared this test. ELCDL is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing.

This is an LDT for use in the United States only and cannot currently be used for patients in New York, California, Maryland, Pennsylvania, Rhode Island, or Washington DC until state-specific approval is granted.

References/Supporting Literature

- Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer's disease in clinical practice and trials. Nat Aging. 2023 May;3(5):506-519. doi: 10.1038/s43587-023-00403-3.

- Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8(1):1-13. doi:10.1016/j.jalz.2011.10.007

- Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216. doi:10.1016/S1474-4422(12)70291-0

- Jack CR Jr, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-547. doi:10.1212/WNL.0000000000002923

- Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018

- Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989-997. doi:10.1016/j.jalz.2018.02.013

- Palmqvist S, Insel PS, Stomrud E, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Mol Med. 2019;11(12):e11170. doi:10.15252/emmm.201911170

- Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020;324(8):772-781. doi:10.1001/jama.2020.12134

- Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387-397. doi:10.1038/s41591-020-0762-2

- Belloy ME, Andrews SJ, Le Guen Y, et al. APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry. JAMA Neurol. 2023;80(12):1284–1294. doi:10.1001/jamaneurol.2023.3599

- Jack CR Jr, et al., Alzheimers Dement. 2024; In Press.

Eli Lilly Clinical Diagnostics Laboratory